Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Lamassu Pharma

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RABI-767

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: RABI-767

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $1.5 million Upfront Cash: Undisclosed

            Deal Type: Funding July 14, 2020

            Details:

            The SBIR grant will be used for further development of company's lead therapeutic compound, RABI-767, a novel small molecule lipase inhibitor licensed from the Mayo Foundation for Medical Education and Research.